Structures by: Sun C. C.
Total: 38
SMT-SAC salt
C19H19N5O5S2
CrystEngComm (2019) 21, 13 2089
a=10.4993(5)Å b=16.0117(8)Å c=25.1481(12)Å
α=90.00° β=90.00° γ=90.00°
C19H19N5O5S2
C19H19N5O5S2
CrystEngComm (2019) 21, 13 2089
a=8.0291(2)Å b=17.5002(4)Å c=14.6076(3)Å
α=90.00° β=107.8270(10)° γ=90.00°
Potassium hydrogen bis(benzoate)
C14H11KO4
CrystEngComm (2013) 15, 29 5756
a=29.585(13)Å b=3.8211(18)Å c=11.156(5)Å
α=90.00° β=97.327(5)° γ=90.00°
Ammonium hydrogen bis(benzoate)
C14H15NO4
CrystEngComm (2013) 15, 29 5756
a=29.234(10)Å b=3.8543(13)Å c=11.408(4)Å
α=90.00° β=94.455(5)° γ=90.00°
Nicotinamide hydrochloride base salt
C12H15ClN4O3
CrystEngComm (2012) 14, 11 3851
a=6.8600(10)Å b=8.7768(12)Å c=11.8950(16)Å
α=78.960(2)° β=82.287(2)° γ=80.200(2)°
Sodium hydrogen bis(naproxate) methanol solvate
C30H35NaO8
CrystEngComm (2012) 14, 11 3851
a=8.8921(12)Å b=5.7750(8)Å c=26.920(4)Å
α=90.00° β=95.899(3)° γ=90.00°
Naproxen sodium mono salt DMF solvate
C17H20NNaO4
CrystEngComm (2012) 14, 11 3851
a=8.5777(12)Å b=5.8968(8)Å c=16.506(2)Å
α=90.00° β=92.350(2)° γ=90.00°
Acetaminophen hydrochloride hydrate
C8H12ClNO3
CrystEngComm (2012) 14, 7 2389
a=6.2761(6)Å b=22.345(2)Å c=6.8833(7)Å
α=90.00° β=97.2570(10)° γ=90.00°
4-hydroxybenzenaminium chloride
C6H8ClNO
CrystEngComm (2012) 14, 7 2389
a=6.4919(6)Å b=6.1159(6)Å c=16.8700(16)Å
α=90.00° β=90.0320(10)° γ=90.00°
Ammonium benzoate
C7H9NO2
CrystEngComm (2013) 15, 29 5756
a=6.8750(11)Å b=6.9872(11)Å c=30.188(5)Å
α=90.00° β=90.00° γ=90.00°
1-ferrocenylethanol
C12H14FeO
Journal of the Chemical Society, Dalton Transactions (1998) 8 1269
a=23.132(2)Å b=23.132(2)Å c=7.5720(10)Å
α=90.00° β=90.00° γ=90.00°
1-ferrocenylethyl p-nitrobenzoate
C19H17FeNO4
Journal of the Chemical Society, Dalton Transactions (1998) 8 1269
a=7.325(2)Å b=7.2810(10)Å c=17.488(4)Å
α=88.76(2)° β=79.26(2)° γ=61.31(2)°
1-ferrocenylethyl benzoate
C19H18FeO2
Journal of the Chemical Society, Dalton Transactions (1998) 8 1269
a=7.8523(9)Å b=9.7282(9)Å c=20.154(3)Å
α=90.00° β=92.720(10)° γ=90.00°
1-ferrocenylethyl benzoate
C19H18FeO2
Journal of the Chemical Society, Dalton Transactions (1998) 8 1269
a=9.415(2)Å b=19.390(4)Å c=8.845(3)Å
α=90.00° β=109.87(2)° γ=90.00°
Ethenzamide hydrochloride salt
C9H12ClNO2
CrystEngComm (2013) 15, 44 8941
a=7.5611(6)Å b=14.9501(11)Å c=10.3894(6)Å
α=90.00° β=123.740(4)° γ=90.00°
Ethenzamide hydrobromide salt
C9H12BrNO2
CrystEngComm (2013) 15, 44 8941
a=7.6316(6)Å b=15.2521(11)Å c=10.6249(6)Å
α=90.00° β=124.184(4)° γ=90.00°
Salicylamide hydrochloride salt
C7H8ClNO2
CrystEngComm (2013) 15, 44 8941
a=9.0833(6)Å b=5.1811(4)Å c=16.3294(11)Å
α=90.00° β=91.0110(10)° γ=90.00°
Ethenzamide HNO3 salt
C54H57N15O37
CrystEngComm (2013) 15, 44 8941
a=38.522(5)Å b=38.522(5)Å c=3.9027(5)Å
α=90.00° β=90.00° γ=120.00°
SalicylamidE HNO3 salt
C7H8N2O5
CrystEngComm (2013) 15, 44 8941
a=10.2073(7)Å b=5.0535(3)Å c=16.9090(11)Å
α=90.00° β=104.7910(10)° γ=90.00°
Salicylamide HClO4 salt
C7H8ClNO6
CrystEngComm (2013) 15, 44 8941
a=18.6631(17)Å b=5.1858(5)Å c=20.1660(18)Å
α=90.00° β=106.8520(10)° γ=90.00°
Phenacetin hemi hydrochloride
C20H27ClN2O4
CrystEngComm (2013) 15, 44 8941
a=26.813(5)Å b=5.6138(11)Å c=13.838(3)Å
α=90.00° β=90.014(2)° γ=90.00°
Acetaminophen hydrobromide monohydrate salt
C8H12BrNO3
CrystEngComm (2013) 15, 44 8941
a=5.8473(4)Å b=23.1474(15)Å c=7.2982(5)Å
α=90.00° β=95.9480(10)° γ=90.00°
Phenacetin hydrochloride salt trihydrate
C20H33Cl2N2O7
CrystEngComm (2013) 15, 44 8941
a=6.7923(4)Å b=13.4759(8)Å c=14.1913(8)Å
α=76.1270(10)° β=77.3120(10)° γ=87.9620(10)°
Phenacetin hemi hydrobromide
C20H27BrN2O4
CrystEngComm (2013) 15, 44 8941
a=13.3000(7)Å b=12.1554(7)Å c=28.5010(14)Å
α=90.00° β=111.742(2)° γ=90.00°
Phenacetin hydrobromide trihydrate
C20H33Br2N2O7
CrystEngComm (2013) 15, 44 8941
a=6.8379(8)Å b=13.7200(16)Å c=14.2131(17)Å
α=76.208(2)° β=77.572(2)° γ=87.122(2)°
Sodium dihydrogen tris(benzoate)
C21H17NaO6
CrystEngComm (2013) 15, 29 5756
a=5.8207(11)Å b=14.460(3)Å c=22.090(4)Å
α=90.00° β=97.084(3)° γ=90.00°
Theoph methyl gal cocrystal
C7H8N4O2,C8H8O5
CrystEngComm (2010) 12, 8 2466
a=10.2745(7)Å b=10.1246(7)Å c=14.8789(10)Å
α=90.00° β=98.865(2)° γ=90.00°
Methylgallate
C8H8O5
CrystEngComm (2010) 12, 8 2466
a=7.6798(12)Å b=9.9854(15)Å c=10.5949(16)Å
α=90.00° β=96.005(2)° γ=90.00°
Celecoxib dimethylformamide monosolvate
C17H14F3N3O2S,C3H7NO
Acta Crystallographica Section C (2020) 76, 7
a=11.8973(4)Å b=8.8360(3)Å c=21.8286(7)Å
α=90° β=103.4537(13)° γ=90°
Celecoxib dimethylacetamide monosolvate
C17H14F3N3O2S,C4H9NO
Acta Crystallographica Section C (2020) 76, 7
a=11.9584(3)Å b=9.2028(2)Å c=21.2811(6)Å
α=90° β=103.3826(12)° γ=90°
Celecoxib 1,3-dimethyltetrahydropyrimidin-2(1H)-one monosolvate
C17H14F3N3O2S,C6H12N2O
Acta Crystallographica Section C (2020) 76, 7
a=12.4495(17)Å b=8.7822(13)Å c=22.656(3)Å
α=90° β=97.861(5)° γ=90°
Celecoxib <i>N</i>-methyl-2-pyrrolidone monosolvate
C17H14F3N3O2S,C5H9NO
Acta Crystallographica Section C (2020) 76, 7
a=11.9978(4)Å b=9.0896(3)Å c=21.9732(8)Å
α=90° β=101.358(2)° γ=90°
Celecoxib tetramethylurea monosolvate
C17H14F3N3O2S,C5H12N2O
Acta Crystallographica Section C (2020) 76, 7
a=12.4050(3)Å b=8.9351(2)Å c=22.5727(6)Å
α=90° β=98.6702(13)° γ=90°
Celecoxib dimethyl sulfoxide monosolvate
C17H14F3N3O2S,C2H6OS
Acta Crystallographica Section C (2020) 76, 7
a=11.9884(3)Å b=9.0230(3)Å c=20.8537(6)Å
α=90° β=100.3908(9)° γ=90°
Celecixib
C17H14F3N3O2S
Chemistry of Materials (2019) 31, 5 1794
a=5.0627(5)Å b=10.0139(11)Å c=16.3981(17)Å
α=89.874(4)° β=85.867(3)° γ=80.530(4)°
Lamivudinium hemiOxalate
C18H24N6O10S2
Crystal Growth & Design (2014) 14, 8 3990
a=6.6714(11)Å b=9.1340(15)Å c=37.650(6)Å
α=90.00° β=90.00° γ=90.00°
Lamivudinium Oxalate monohydrate
C10H15N3O8S
Crystal Growth & Design (2014) 14, 8 3990
a=8.6175(9)Å b=24.679(3)Å c=13.4297(14)Å
α=90.00° β=101.0020(10)° γ=90.00°
Ethenzamide HClO4 salt
C9H12ClNO6
CrystEngComm (2013) 15, 44 8941
a=6.7925(17)Å b=14.670(4)Å c=11.674(3)Å
α=90.00° β=95.785(3)° γ=90.00°